

## AMENDMENT

### In the claims:

Claims 1-16 (Canceled).

Claim 17 (Previously Amended). An injectable formulation, comprising:

- (a) particles comprising a biocompatible polymeric matrix, the matrix comprising a poly(lactide-co-glycolide);
- (b) a biologically active polypeptide dispersed within the matrix; and
- (c) an injection vehicle comprising hyaluronic acid dissolved in a physiological buffer.

Claims 18-19 (Canceled).

Claim 20 (Currently Amended). A method for administering a biologically active agent polypeptide, comprising:

- injecting the formulation of claim 17 into a patient in need thereof through a 23-gauge or smaller needle,
- wherein the particles have an average diameter of between about 5 and about 200 microns.

Claim 21 (Previously Amended). An injectable formulation, comprising:

- (a) hyaluronic acid dissolved in a physiological buffer; and
- (b) particles, comprising:
  - (i) a biologically active agent, and
  - (ii) a biocompatible polymeric matrix.

Claim 22 (Previously Added). The injectable formulation of claim 21, wherein the concentration of hyaluronic acid is about 0.01 to about 0.8 percent weight per volume.

Claim 23 (Previously Added). The injectable formulation of claim 21, wherein the hyaluronic acid is dissolved in physiological saline.

Claim 24 (Cancelled).

Claim 25 (Previously Added). The injectable formulation of claim 21, wherein the polymeric matrix comprises a polymer selected from the group consisting of blocked polymers and unblocked polymers.

Claim 26 (Previously Added). The injectable formulation of claim 21, wherein the polymeric matrix comprises a polymer selected from the group consisting of blocked polymers and unblocked polymers.

Claim 27 (Previously Added). The injectable formulation of claim 21, wherein the polymer is a poly(lactide-co-glycolide).

Claim 28 (Previously Added). The injectable formulation of claim 21, wherein the biologically active agent is a polypeptide.

Claim 29 (Previously Amended) The injectable formulation of claim 28, wherein the polypeptide is selected from the group consisting of a growth hormone, a hepatocyte growth factor (HGF), a vascular endothelial growth factor (VEGF), a glucagon-like peptide I (GLP-I), a nerve growth factor, an insulin-like growth factor, and an antibody.

Claim 30 (Currently Amended). The injectable formulation of claim 21, wherein the concentration of the polymeric matrix ~~comprising the biologically active agent~~ is about 1 mg/mL to about 500 mg/mL of formulation.

Claim 31 (Currently Amended). The injectable formulation of claim 21, wherein the concentration of the polymeric matrix ~~comprising the biologically active agent~~ is about 1 mg/mL to about 300 mg/mL of formulation.

Claim 32 (Cancelled).

Claim 33 (Previously Amended) The injectable formulation of claim 21, wherein the hyaluronic acid is N-acylurea modified hyaluronic acid.

Claim 34 (Previously Added). The injectable formulation of claim 21, wherein the hyaluronic acid is sodium hyaluronate.

Claim 35 (Previously Amended). The injectable formulation of claim 17, wherein the polypeptide is selected from the group consisting of a growth hormone, a hepatocyte growth factor (HGF), a vascular endothelial growth factor (VEGF), a glucagon-like peptide I (GLP-I), a nerve growth factor, an insulin-like growth factor, and an antibody.

Claim 36 (Previously Added). The injectable formulation of claim 29, wherein the polypeptide is an anti-vascular endothelial growth factor Fab (anti-VEGF Fab).

Claim 37 (Previously Added). The injectable formulation of claim 35, wherein the polypeptide is an anti-vascular endothelial growth factor Fab (anti-VEGF Fab).

### **Support for the Amendments**

Support for the amended claims 20, 30, and 31 can be found on page 8, lines 22-23 and page 9, lines 2-3 of the originally-filed application. Claims 17, 20-23, 25-31 and 33-37 are pending in the application. This amendment contains no new matter.